Clear All
765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9306 Pertuzumab Perjeta 1 mg Immunotherapy Monoclonal Antibody HER2 No 2012 Jan 1, 2014 In Use
J9274 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Sep 27, 2022 In Use
J9272 Dostarlimab-gxly Jemperli 10mg Immunotherapy Checkpoint Inhibitor PD-1 No 2021 Jan 26, 2022 In Use
C9472 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Apr 1, 2016 In Use
J9311 Rituximab and Hyaluronidase Rituxan Hycela 10mg Immunotherapy Monoclonal Antibody CD20 No 2017 Jan 1, 2019 In Use
Q5123 Rituximab-arrx Riabni 10mg Immunotherapy Monoclonal Antibody CD20 No 2021 Jul 23, 2021 In Use
J9325 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Jan 1, 2017 In Use
J9303 Panitumumab Vectibix 10mg Immunotherapy Monoclonal Antibody EGFR No 2006 Jan 1, 2008 In Use
J9347 Tremelimumab-actl Imjudo 1mg Immunotherapy Monoclonal Antibody CTLA-4 No 2022 Jul 11, 2023 In Use
J9276 Zanidatamab-hrii ZIIHERA 2mg Immunotherapy Bispecific Antibody HER2 No 2024 Jul 9, 2025 In Use
C9021 Obinutuzumab Gazyva 10 mg Immunotherapy Monoclonal Antibody CD20 No 2013 Apr 4, 2014 Dec 31, 2014 No Longer Used
J1326 Zolbetuximab-clzb Vyloy 2mg Immunotherapy Monoclonal Antibody CLDN18.2 No 2024 Jul 9, 2025 In Use
Q2057 Afamitresgene autoleucel Tecelra per therapeutic dose Immunotherapy T Cell Receptor (TCR) MAGE-A4 No 2024 Mar 26, 2025 In Use
J9302 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 Jan 1, 2011 In Use
J9316 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf Phesgo 10mg Immunotherapy Monoclonal Antibody HER2 No 2020 Jan 1, 2021 In Use
J9354 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jan 1, 2014 In Use
Q5112 Trastuzumab-dttb Ontruzant 10mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 1, 2019 In Use
C9117 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct 1, 2002 Dec 31, 2002 No Longer Used
J9361 Efbemalenograstim alfa-vuxw Ryzneuta 0.5mg Immunotherapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2023 Jun 10, 2024 In Use
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct 1, 2002 Dec 31, 2002 No Longer Used
Q5126 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Nov 28, 2022 In Use
J9356 Trastuzumab and Hyaluronidase-oysk Herceptin hylecta 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Jul 1, 2019 In Use
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 Jul 1, 2019 In Use
C9455 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 Jul 1, 2015 Dec 31, 2015 No Longer Used
J9355 Trastuzumab Herceptin 10 mg Immunotherapy Monoclonal Antibody HER2 No 1998 Jan 1, 2000 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.